Skip to main content
Headlines

In the News

In the News highlights media coverage featuring the Johns Hopkins Bloomberg School of Public Health.

WTOP
|

FDA panel backs Pfizer’s low-dose COVID-19 vaccine for kids

A Food and Drug Administration advisory panel voted unanimously, with one abstention, that the vaccine’s benefits in preventing COVID-19 in that age group outweigh any potential risks. That includes questions about a heart-related side effect that’s been very rare in teens and young adults despite their use of a much higher vaccine dose.

Verywell Health
|

WHO Releases First Official Long COVID Definition

Long COVID has been used to refer to a range of new, returning, or ongoing symptoms after initial COVID-19 infection. This month, the WHO has published an official definition of post-COVID-19 to advance research and help diagnose individuals.
 

The Washington Post
|

FDA review appears to pave the way for Pfizer-BioNTech vaccine for children 5 to 11

The Pfizer-BioNTech coronavirus vaccine appears poised to become available to children 5 to 11 years old within weeks, after a Food and Drug Administration review found the benefits of the shot outweigh the risks in most scenarios, with the possible exception of when there are very low levels of viral transmission.